Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma
Qiyan Wang, Ting Su, Furong Cheng, Shurong Zhou, Xiang Liu, Mi Wang, You Xu, Ri Tang, Shimiao Liao, Jordan M. Dailey, Guolan Xiao, Chunpeng Yang, Hanning Wen, Weijia Zheng, Bo Wen, , Guizhi Zhu
This paper introduces PROTAVs, a new vaccine strategy that enhances T cell responses and combination immunotherapy for melanoma by improving antigen processing and cross-presentation.
bioRxiv · Oct 1, 2024 · PreprintBioengineering